Natera, Inc. - Common Stock (NQ:NTRA)

420.58 +10.23 (+2.49%)

Delayed Quote Updated: 2:29 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Analyst Ratings For Natera ↗

June 22, 2021

Within the last quarter, Natera (NASDAQ:NTRA) has observed...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

June 21, 2021

SVB Leerink raised Natera, Inc. (NASDAQ:NTRA) pr...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 ↗

June 15, 2021

Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an...

Via Benzinga

Expert Ratings for Natera ↗

May 25, 2021

Analysts have provided the following ratings for Natera (NASDAQ:NTRA) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 0 0...

Via Benzinga

Natera: Q1 Earnings Insights ↗

May 06, 2021

Shares of Natera (NASDAQ:NTRA) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 64.44% over the past year to ($0.74),...

Via Benzinga

Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera

June 08, 2021

From Foundation Medicine

Via Business Wire

Exact Sciences' First-Quarter Results Show Its Strength Under Pressure ↗

May 15, 2021

Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate?

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 06, 2021

Gainers T2 Biosystems (NASDAQ:TTOO) share...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 ↗

May 25, 2021

Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to...

Via Benzinga

Cramer Gives His Opinion On ContextLogic, Microvision And More ↗

April 27, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer said he bets there could be a bit of a run in ContextLogic Inc. (NASDAQ: WISH) because 40% of the float is shorted...

Via Benzinga

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗

May 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.